Payment overview · 2025
General Payments
$42,664.99
132 reported records · 16 companies
Healthcare provider profile · identity verified
Lisa B. Connery, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · NORMAN, OK · NPI 1205828977
Verified facts
What the public records show
CMS Open Payments records show Lisa B. Connery, M.D. received $42,664.99 in general payments during 2025 across 132 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 59.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Nexletol, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
AstraZeneca UK Limited reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 30 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Jardiance by this doctor in 2024.
Eli Lilly and Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 15 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Jardiance by this doctor in 2024.
Eli Lilly and Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 176 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Mounjaro by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nexletol by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25,505.08 | 59.8% | 36 | 2025 |
| Eli Lilly and Company | Unresolved — no canonical attribution shown | $13,482.17 | 31.6% | 38 | 2025 |
| AstraZeneca UK Limited | Unresolved — no canonical attribution shown | $2,109.73 | 4.9% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $817.51 | 1.9% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $153.09 | 0.4% | 8 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $149.93 | 0.3% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $96.04 | 0.2% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $75.22 | 0.2% | 4 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $65.45 | 0.1% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $53.26 | 0.1% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $34.99 | 0.1% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $30.68 | 0.1% | 2 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $28.43 | 0.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $26.42 | 0.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.77 | 0.1% | 3 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $15.22 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $25,680.00 | 7 |
| Travel and Lodging | $11,056.68 | 41 |
| Food and Beverage | $3,078.31 | 82 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,850.00 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Eli Lilly and Company, Lilly USA, LLC | $776.42 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $97.80 | 5 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $96.04 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $75.22 | 4 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $65.45 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $53.26 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $44.02 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $40.37 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $34.99 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $33.75 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.86 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $30.68 | 2 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Almatica Pharma LLC | $28.43 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $26.42 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $20.39 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.49 | 2 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $15.22 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $10.53 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $5.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 70 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca UK Limited Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 30 supporting records · 16 recipient NPIs · example record 1202913210 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Eli Lilly and Company Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 11 recipient NPIs · example record 1186556234 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Eli Lilly and Company Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 176 supporting records · 33 recipient NPIs · example record 1186466331 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
70 | 13 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
70 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 329 | 98 |
| Levothyroxine Sodium | Levothyroxine Sodium | 251 | 63 |
| Famotidine | Famotidine | 149 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 138 | 26 |
| Omeprazole | Omeprazole | 132 | 39 |
| Lisinopril | Lisinopril | 129 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 122 | 43 |
| Amlodipine Besylate | Amlodipine Besylate | 115 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 110 | 30 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 98 | 24 |
| Gabapentin | Gabapentin | 90 | 27 |
| Metformin Hcl | Metformin Hcl | 88 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 84 | 21 |
| Mounjaro | Tirzepatide | 70 | 13 |
| Estradiol | Estradiol | 68 | 23 |
| Alendronate Sodium | Alendronate Sodium | 56 | 18 |
| Trazodone Hcl | Trazodone Hcl | 55 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 14 |
| Jardiance | Empagliflozin | 49 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 47 | 18 |
| Meloxicam | Meloxicam | 45 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 41 | suppressed |
| Eliquis | Apixaban | 39 | suppressed |
| Glimepiride | Glimepiride | 38 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 35 | suppressed |
| Potassium Chloride | Potassium Chloride | 35 | suppressed |
| Ezetimibe | Ezetimibe | 34 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 33 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 33 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 32 | suppressed |
| Methocarbamol | Methocarbamol | 31 | 14 |
| Sertraline Hcl | Sertraline Hcl | 31 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 30 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 30 | 11 |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 27 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Cephalexin | Cephalexin | 24 | 17 |
| Valsartan | Valsartan | 24 | suppressed |
| Losartan Potassium | Losartan Potassium | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Clonidine | Clonidine | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 22 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 19 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 18 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Simvastatin | Simvastatin | 18 | suppressed |
| Alprazolam | Alprazolam | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 17 | suppressed |
| Furosemide | Furosemide | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 13 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Forteo | Teriparatide | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Qulipta | Atogepant | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Nexletol | Bempedoic Acid | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Ozempic | Semaglutide | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Savella | Milnacipran Hcl | 11 | suppressed |
| Triamterene | Triamterene | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $42,664.99 · 132 records | Boehringer Ingelheim Pharmaceuticals, Inc. | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, EVENITY, FARXIGA, Kerendia, MOUNJARO, NEXLETOL, OTEZLA, Ozempic, PROLIA, REPATHA, TERIPARATIDE, Tymlos, VRAYLAR, Wegovy, Yorvipath, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error